Abstract
Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Current Neuropharmacology
Title: Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Volume: 3 Issue: 4
Author(s): Y. Zhang and H. K. Kimelberg
Affiliation:
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Abstract: Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Export Options
About this article
Cite this article as:
Zhang Y. and Kimelberg K. H., Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia, Current Neuropharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157015905774322534
DOI https://dx.doi.org/10.2174/157015905774322534 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review
Current Vascular Pharmacology The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis
Current Vascular Pharmacology Editorial (Hot Topic: Neuroprotection and Neuroregeneration in Ischemic Stroke: Emerging Treatment Strategies and Potential Molecular Targets)
Current Drug Targets Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Methods of Puerarin Biotransformation
Mini-Reviews in Medicinal Chemistry Analysis of Hypoxiamir-Gene Regulatory Network Identifies Critical MiRNAs Influencing Cell-Cycle Regulation Under Hypoxic Conditions
MicroRNA A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment
Current Drug Targets Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury
Current Molecular Medicine Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Connexin43 and Myocardial Ischemia-Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry